[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ketogenic-dieting\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ketogenic-dieting":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,73,100,137,160,188,215],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100524940","ketogenic-diet-and-diabetes-demonstration-project-100524940",false,"NCT06115265","Ketogenic Diet and Diabetes Demonstration Project","KDDP","Inclusion Criteria:\n\n* Men and women ≥ 18 years old\n* BMI ≥27 kg\u002Fm2\n* Hemoglobin A1c ≥ 5.7% and\u002For fasting plasma glucose of 100-125 mg\u002FdL\n\nExclusion Criteria:\n\n* Known clinical cardiovascular disease (i.e. prior stroke, myocardial infarction, peripheral artery disease)\n* LDL cholesterol ≥ 190 mg\u002FdL\n* Triglycerides ≥ 500 mg\u002FdL\n* History of type 1 diabetes\n* History of diabetic ketoacidosis\n* Individuals requiring insulin\n* Advanced renal disease\n* Advanced liver disease\n* Terminal cancer\n* Pregnancy",true,"ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","KDDP is a prospective, 12-month pilot study comparing the effects of a novel lifestyle program, the Ketogenic Diet and Diabetes Demonstration Project (KDDP) to those of the National Diabetes Prevention Program (NDDP). KDDP is modeled to mimic the delivery platform of NDPP with the exception that participants in KDDP will be placed on a medically-supervised ketogenic diet, and participants in NDPP will be placed on a low fat diet.\n\nThe purpose of this study is to compare the metabolic effects of the KDDP and the NDPP on glycemic control, lipid parameters, blood pressure, heart rate, weight, and coronary artery calcium scores in individuals with either type 2 diabetes or prediabetes.",[27,28,29,30],"Type 2 Diabetes","PreDiabetes","Obesity","Ketogenic Dieting","RECRUITING","2026-06-26",{"date":34,"type":35},"2026-06-30","ACTUAL",{"date":37,"type":35},"2023-09-05",{"date":39,"type":21},"2026-10-01",{"name":41,"class":42},"University of New Mexico","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100383555","phase-3-ketogenic-diet-for-new-onset-absence-epilepsy-100383555","NCT04274179","Ketogenic Diet for New-Onset Absence Epilepsy","A Prospective, Case-control Evaluation of Ketogenic Dietary Therapy for New-onset Childhood Absence Epilepsy","Inclusion Criteria:\n\n* Children ages 3-12 years at seizure onset with classic childhood absence epilepsy clinically.\n* Normal intellect or mild disability\n* EEG with confirmed 3\u002Fsecond spike-wave discharges, usually with hyperventilation\n* Daily reported absence seizures.\n* Generalized convulsions allowed\n\nExclusion Criteria:\n\n* Previous treatment with any anticonvulsant drug\n* Previous use of a ketogenic dietary therapy for epilepsy or any other condition\n* Glut1 deficiency syndrome\n* Metabolic disorder known that would preclude dietary therapy\n* Dietary restrictions for which a high fat, low carbohydrate diet would be precluded.\n* Prior history of epilepsy (febrile seizures allowed)\n* Unwilling to consent to study procedures or return for visits","3 Years","12 Years",{"count":20,"type":21},[55],"PHASE3","The ketogenic diet is a medical therapy for epilepsy that is used nearly predominantly for refractory epilepsy (after 2-3 drugs have been tried and failed). However, there is both published evidence for first-line use (infantile spasms, Glut1 deficiency syndrome) and also anecdotal experience (families choosing to change the child's (or the family' own) diet rather than use anticonvulsant medications). Childhood absence epilepsy (refractory) has been published as being responsive to ketogenic diet therapy by the investigators' group previously. This is a small, prospective, 3 month trial to assess if using a modified Atkins diet is a feasible and effective option for new-onset childhood absence epilepsy. The investigators will compare to a group of children in which the parents have declined and chose to start anticonvulsant medications.",[58,30,59],"Absence Epilepsy","Epilepsy, Absence",[61,62,63],"ketogenic","diet","absence","2026-05-05",{"date":66,"type":35},"2026-05-07",{"date":68,"type":35},"2020-08-10",{"date":70,"type":21},"2028-05-01",{"name":72,"class":42},"Johns Hopkins University",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":43},"100361879","nutritional-ketosis-a-novel-metabolic-strategy-to-treat-lymphedema-patients-100361879","NCT03991897","Nutritional Ketosis: a Novel Metabolic Strategy to Treat Lymphedema Patients?","KETOLYMPH","Inclusion Criteria:\n\n* \\>18 years;\n* unilateral lymphedema of the arm lymph node dissection\n* lymphedema onset less than a year before the therapy starts\n* lymphedema defined as \\>3% volume difference between both arms\n* lymphedema stage 1, stage 2a or stage 2b\n* absence of pregnancy at the time of enrollment and willingness to use adequate contraceptive measures until the end of the study;\n* oral and written approval of the informed consent presented at the time of the consultation by the physicians;\n* understanding Dutch\n\nExclusion Criteria:\n\n* \\\u003C18 years;\n* edema of the limb with different etiology or later stage\u002Fonset as specified in the inclusion criteria;\n* presence of active cancer\n* pregnancy or active breastfeeding;\n* impossibility to participate for the entire study period;\n* mentally or physically unable to participate to the study;\n* presence of gastrointestinal intolerance or other serious illness (e.g. renal failure, hepatic dysfunction, heart failure, neurological impairment);\n* presence of diabetes or other metabolic disease;\n* contra-indication for the use of indocyanine green (ICG): allergy to ICG or iodine, hyperthyroidism.",{"count":81,"type":21},81,[24],"Lymphedema is a debilitating disorder that severely impairs the quality of life of the patients and requires life-long attention. Treatment for lymphatic dysfunction remains largely symptomatic, without real cure. According to the International Society of Lymphology, lymphedema has to be treated with Decongestive Lymphatic Therapy.\n\nResearch in the lab of Angiogenesis and Vascular Metabolism (PCA lab) reported in mice that metabolism of endothelial cells controls vessel sprouting. Experiments showed that a ketogenic diet (KD) reduced the edema of the mice tail and enhanced the lymphatic transport. Based on these proof-of-concept data, the investigators plan to test this innovative concept to ameliorate lymph vessel dysfunction in lymphedema patients. Randomisation will be performed between a ketogenic diet and an isocaloric diet with and without ketone ester supplementation.",[85,30,86],"Lymphedema","Ketone Ester Supplement",[88,89,90],"ketosis","lymphedema","dermal backflow","2025-11-25",{"date":93,"type":35},"2025-12-03",{"date":95,"type":35},"2025-10-01",{"date":97,"type":21},"2028-08-01",{"name":99,"class":42},"Universitaire Ziekenhuizen KU Leuven",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":122,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":43},"100573643","ketogenic-metabolic-therapy-in-schizophrenia-bipolar-disorder-major-depressive-disorder-deep-omic-profiling-100573643","NCT06748950","Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling","A Randomized Controlled Trial of a Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling","Inclusion Criteria:\n\n1. diagnosed with bipolar disorder (BD), major depressive disorder (MDD), and or schizophrenia\n\n   1. For individuals diagnosed with bipolar disorder (BD):\n\n      * Meet DSM V criteria for BD (any subtype)\n      * Not mild\n      * \\>40 on BPRS\n      * clinically stable (with no hospitalization for past 3 months)\n   2. For individuals diagnosed with major depressive disorder (MDD):\n\n      * Not mild\n      * PHQ-9 \\> 10\n      * clinically stable (with no hospitalization for past 3 months)\n   3. For individuals diagnosed with schizophrenia:\n\n      * Meet DSM V criteria for schizophrenia (any subtype)\n      * Not mild\n      * \\>40 on BPRS\n      * clinically stable (with no hospitalization for past 3 months)\n2. Participants may currently be on a stable and adequate dose of SSRI antidepressant therapy or other psychiatric medication. Concurrent hypnotic therapy (e.g., with zolpidem, zaleplon, melatonin, or trazodone) will be allowed if the therapy has been stable for at least four weeks prior to screening and if it is expected to remain stable. Participants may be switched from other classes of medication to another medication class by their psychiatrist or primary care doctor, but need to be stable enough to enroll and adhere to study procedures.\n3. willing and able to give informed consent for participation in English.\n4. live within the United States.\n\n   \\--------------------------------------------------------------------------------\n\nExclusion Criteria:\n\n1. has started the ketogenic diet or was in ketosis within 3 months of wanting to enroll\n2. pregnant or nursing\n3. insulin dependent\n4. comorbidity of developmental delay\n5. in a current severe mood or psychotic state when entering the study that would prohibit compliance with study visits or dietary programs.\n6. any one who has been hospitalized or taken clozapine at doses above 550mg over the past 3 months\n7. inability to complete baseline measurements\n8. severe renal or hepatic insufficiency\n9. cardiovascular dysfunction, including diagnosis of:\n\n   * Congestive heart failure\n   * Angina\n   * Arrhythmias\n   * Cardiomyopathy\n   * Valvular heart disease\n10. active substance abuse with illicit drugs or alcohol and\u002For current diagnosis of a Substance Use Disorder (Abuse or Dependence, as defined by DSM-IV-TR), with the exception of nicotine or cannabis dependence\n11. active suicidal and considered at significant risk for suicide during course of study\n12. participation in any clinical trial- within the past month or concurrent to study participation- with an investigational drug\u002Fdevice and\u002For intervention that may interfere with study participation\u002Fevaluation of results\n13. mild BPRS at screening or baseline visits\n14. history of TBI\n15. any other medical condition that may make diet intervention dangerous as determined by the study medical team (e.g. anorexia nervosa) or assessed by study team to have insufficient control over their food intake to adhere to study diets.\n16. any medical condition that physicians or the PI believe would interfere with study participation or evaluation of results\n17. history of familial hypercholesterolemia","80 Years",{"count":109,"type":21},120,[24],"The goal of this randomized clinical trial is to be adequately powered to evaluate the effect of ketogenic metabolic therapy on the quality of life in serious mental illness, schizophrenia, bipolar disorder, major depressive disorder.",[113,114,115,116,117,118,30,119,120,121],"Schizophrenia","Schizophrenia and Related Disorders","Bipolar Disorder","Bipolar and Related Disorders","Major Depressive Disorder","Major Depression Severe","Ketosis","Metabolic Disease","Metabolic Syndrome",[123,124,125,126],"Mental Illness","Multiomics","Multi-omics","Omics Profiling","NOT_YET_RECRUITING","2025-05-13",{"date":130,"type":35},"2025-05-16",{"date":132,"type":21},"2025-07",{"date":134,"type":21},"2028-07",{"name":136,"class":42},"Stanford University",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":43},"100581452","ketogenic-diet-prior-to-bariatric-surgery-100581452","NCT06850493","Ketogenic Diet Prior to Bariatric Surgery","The Impact of a Preoperative Very Low Calorie Ketogenic Diet (VLCKD) on Body Composition in Patients Undergoing Bariatric Surgery: a Randomised Controlled Trial","Inclusion Criteria:\n\n* Eligible for bariatric surgery (≥35 kg\u002Fm2 with obesity-related comorbidities, or a BMI of\n\n  * 40 kg\u002Fm2 with or without comorbidities)\n* Roux-en-Y Gastric bypass (RYGB)\n\nExclusion Criteria:\n\n* Weighing over 150kg because this amount is a limitation by the DXA device\n* Diabetes mellitus type 1\n* Allergic to milk proteins\n* A recent history of a heart attack (\\\u003C 12 months), heart failure or cardiac arrhythmias\n* Kidney and\u002For liver failure (creatinine levels \\>1.3 mg\u002Fdl or liver enzyme levels (AST, ALT, GGT)) less than three times over the upper normal threshold\n* Current infectious, sepsis or malignant disease\n* Rare condition like galactosemia, phenylketonuria or porphyria\n* Persistent diarrhoea\n* Hypokalaemia, chronic therapies with diuretics as furosemide and hydrochlorothiazide\n* Pregnancy or plans to get pregnant in the coming months\n* Patients who did not meet criteria to be eligible for bariatric surgery (BMI \\\u003C35, psychological or unstable psychiatric disorders, inadequate dietary regimen or inadequate exercise pattern which can't be resolved in the upcoming 6 months)","65 Years",{"count":146,"type":21},46,[24],"Standard dietary regiments for bariatric are advised prior to surgery. The most used diet is a very low calorie diet (VLCD). These diets potentially have multiple pittfalls.\n\nVery low-calorie ketogenic diets (VLCKD) have been proposed as a new regimen for achieving weight- and liver volume loss in patients undergoing bariatric surgery. The beneficial effect of VLCKDs compared to (V)LCDs is the aimed preservation of FFM and RMR, while still reducing FM. Only a few small studies addressed the role of VLCKDs prior to bariatric surgery, and the data including FFM and FM is actually scarce. Therefore, a well-designed randomised controlled trial is necessary to establish the efficacy of a VLCKD.",[150,30],"Bariatric Surgery Candidate","2025-02-24",{"date":153,"type":35},"2025-02-27",{"date":155,"type":35},"2022-09-01",{"date":157,"type":21},"2025-12",{"name":159,"class":42},"Maxima Medical Center",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":175,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100557200","deliket-substudy-of-ketonifast-study-id-22-13981-100557200","NCT06535022","DeliKet (Substudy of KetoNiFast Study ID 22-1398_1)","Impact of Cyclic, Daytime Enteral Nutrition and Ketogenic Nighttime Fasting on the Incidence of Postoperative Delirium in Critically Ill Patients","DeliKet","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Admission to an ICU\n* Start of enteral nutrition\n\nExclusion Criteria:\n\n* Severe liver insufficiency \u002F liver disease (Child Pugh \\> B or 7-9 points)\n* Post total Pancreatectomy \u002F Insulin-depending diabetes mellitus (IDDM)\n* Pregnancy \u002F Lactation\n* Hemoglobin-concentration \\\u003C 80g\u002Fl\n* Severe metabolic disorder \u002F severe autoimmune disease\n* Refractory respiratory or metabolic acidosis\n* Disorder of mitochondrial transportation of fatty acids\n* Disorder of the oxidation of fatty acids\n* Disorder of gluconeogenesis, der ketone body production or ketone body degradation\n* Intermittent porphyria\n* Severe arrhythmia \u002F cardiomyopathy\n* Contraindications against enteral nutrition\n* Missing informed consent",{"count":169,"type":21},90,[24],"Postoperative delirium is a common problem of the critically ill patient and associated with an increased mortality. Intermittent fasting and ketogenesis have been shown to be beneficial for maintaining a circadian rhythm and initiating anti-inflammatory repair mechanisms which could potentially be neuroprotective. However, so far there is little data if cyclic enteral feeding with ketogenic nighttime fasting might be beneficial for reducing the rate of postoperative delirium. The study hypothesis is that equicaloric cyclic enteral feeding (12 hrs) during daytime with ketogenic fasting and exogenous ketone supplementation at nighttime compared to continuous standard enteral nutrition (24 hours) decreases the incidence of postoperative delirium in critically ill patients.",[173,30,174],"Delirium","Nutrition, Healthy",[176,177,178],"ketogenic diet","cyclic nutrition","postoperative delirium","2024-08-04",{"date":181,"type":35},"2024-08-06",{"date":183,"type":21},"2024-09-01",{"date":185,"type":21},"2026-03-01",{"name":187,"class":42},"University Hospital of Cologne",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":195,"maxAge":18,"enrollmentInfo":196,"targetDuration":4,"studyType":198,"phases":4,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":43},"100521891","management-of-drug-resistant-epilepsy-in-infants-and-children-a-real-life-study-of-the-use-of-the-ketogenic-diet-in-france-and-the-ketocal-range-in-its-maintenance-100521891","NCT06075485","Management of Drug-resistant Epilepsy in Infants and Children: a Real-life Study of the Use of the Ketogenic Diet in France and the KetoCal® Range in Its Maintenance","KEOPS","Inclusion Criteria:\n\n* Infants from 5 months and children up to 17 years of age (maximum 18 years minus 1 day).\n* With drug-resistant epilepsy according to ILAE (International League Against Epilepsy) criteria: persistence of epileptic seizures after failure of two appropriate antiepileptic drugs tried consecutively or in well-tolerated combination.\n* Indication for CR by a physician.\n* Parents (or legal guardians) able to set up and follow the diet, assessed during a joint doctor-dietician consultation.\n* Written authorization from one (or both) parents or the child's legal representative to collect personal information about their child.\n* Affiliation of the infant\u002Fchild with the social security system.\n\nExclusion Criteria:\n\n* Contraindication to ketogenic diet at initial assessment.\n* Children already on a ketogenic diet.\n* Parenteral nutrition.\n* Concurrent prescription of other foodstuffs intended for special medical purposes (DADFMS) such as KetoVie or Keyo.\n* Protected legal representative (under legal protection, or deprived of liberty by judicial or administrative decision).\n* Legal representative not covered by a social security scheme.\n* Legal representative unable to understand study protocol.\n\nAncillary study eligibility criteria :\n\n* Patients included in the study.\n* Continued on the ketogenic diet for at least 2 months.\n* Having consented to participate in the ancillary study.","5 Months",{"count":197,"type":21},133,"OBSERVATIONAL","This is a multicenter, prospective, observational, longitudinal study designed to describe the therapeutic value of the KetoCal® range in the maintenance of a ketogenic diet during the management of infants (from 5 months) and children up to 17 years of age (i.e. 18 years minus 1 day) with drug-resistant epilepsy.\n\nThis study is being conducted according to standard medical practice. No change in diagnostic or therapeutic management habits is imposed by this study. Quality of life questionnaires are the only additional procedures for this research.",[201,30],"Drug Resistant Epilepsy",[176,203,204],"epilepsy","drug resistance","2024-01-23",{"date":207,"type":35},"2024-01-24",{"date":209,"type":35},"2024-01-15",{"date":211,"type":21},"2026-06",{"name":213,"class":214},"Nutricia Nutrition Clinique","INDUSTRY",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":43},"100517119","effectiveness-of-ketogenic-diet-in-melas-syndrome-100517119","NCT06013397","Effectiveness of Ketogenic Diet in MELAS Syndrome","Clinical Trial of Ketogenic Diet in the Treatment of Mitochondrial Encephalomyopathy With Lactic Acidosis and Stroke-like Episodes(MELAS)","Inclusion Criteria:\n\n* Patients who meet the diagnostic criteria of MELAS and have received MELAS standard therapy but are not satisfied with the therapeutic effect, and voluntarily underwent ketogenic therapy\n\nExclusion Criteria:\n\n* Diseases with porphyria and disturbances in fatty acid transport and oxidation, severe electrolyte metabolism abnormalities, severe hemodynamic instability, acute respiratory infections, uncontrolled systemic infections, severe liver and renal failure, cholesterolemia (\\>300mgdl), abnormal coagulation, acute pancreatitis, eating disorders, ketogenic diet intolerance, significant weight loss, poor compliance",{"count":223,"type":21},100,[24],"The goal of this clinical trial is to evaluate the effectiveness of ketogenic diet in patients with MELAS syndrome. The main questions it aims to answer are:\n\nClarify the curative effects of ketogenic diet in the treatment of MELAS disease.\n\nPrevent the aggravation of MELAS disease, and improve the quality of life of patients.\n\nProvide reliable evidence-based medical basis for the clinical application of ketogenic diet in the treatment of MELAS syndrome patients.\n\nThe clinical data of the participants treated with ketogenic diet will be collected, including the completion of ketogenic diet and clinical data at the start of treatment and after 1 month, 3 months, 6 months and 12 months",[227,30],"MELAS Syndrome","2023-08-25",{"date":230,"type":35},"2023-08-28",{"date":232,"type":21},"2023-09-01",{"date":234,"type":21},"2038-06-01",{"name":236,"class":42},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]